Clinical Trials

Clinical and Outcomes Research under the direction of the Department of Dermatology is conducted at the Northwestern University Feinberg School of Medicine,  Ann & Robert H. Lurie Children's Hospital of Chicago, and Northwestern Lake Forest Hospital dermatology clinics.

For more information about the research or participation, please call our office at 312-695-6829.

Feinberg Clinical Trials

Scientists at the medical school are conducting hundreds of clinical trials daily. Learn more about all our work via the Feinberg Office of Research Clinical Trials page. Search for trials by disease or condition.

Northwestern University

CoordinatorPIStudy Description
Alba Posligua, MD
alba.posligua( at )northwestern.edu
Joan Guitart MDTitle: A PROspective, observational, U.S.-based study assessing outcomes, adverse events, treatment patterns, and quality of life in patients diagnosed with mycosis fungoides cutaneous T-cell lymphoma (MF-CTCL) and treated with Valchlor
  • 18 years and older
  • Diagnosed with MF-CTCL and being treated with Valchlor
  • Study Duration: 8 visits- once a week
  • IRB Number : STU200362
  • Clinicaltrials.gov ID: NCT02296164
Alba Posligua, MD
alba.posligua( at )northwestern.edu
Anne E Laumann, MBCHBTitle: Pilot study to investigate the molecular effects of topical calcipotriene on morphea
  • 18 years and older
  • clinically-diagnosed or biopsy proven plaque-type, guttate, linear, segmental, and generalized morphea that are receiving calcipotriene 0.005% ointment as part of their standard of care treatment will be included.
  • Study Duration: Visits- 12 weeks long, seen at the start of the trial, two weeks after for suture removal, 12 weeks for the end of study, and 2 weeks after the end of study visit for suture removal only
  • Identifier: STU101294
  • ClinicalTrials.gov ID: NCT02411643
Aleksandra G. Florek, MD
aleksandra.florek( at )northwestern.edu
Bethanee Schlosser, MD, PhD

Title: A Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy and Safety of Once Weekly High Dose Oral Finasteride in the Treatment of Severe Nodulocystic Acne

  • 18-35 years old; Males only
  • A minimum of 10 nodules on the face and/or the trunk (nodule=10mm or more in diameter)
  • Study Duration: 12 week-long trial, 2:1 ratio of active vs. placebo controlled
  • IRB Number: STU00201871
  • ClinicalTrials.gov ID: NCT02502669
Emily Poon Samuelson, PhD
emily.poon( at )northwestern.edu
312-695-4761
Murad Alam, MDTitle: The Effect of Topical Anesthetics on Patients' Pain and Operative Experience During Treatment With QSwitched Laser
  • Female Subjects that are 25 to 65 years old, with moderate lentigines and/or photo damage and desire laser toning
  • Will receive two different topical anesthetics on the forehead, cheeks, and arms.  Patient pain will be rated after q-switch laser to areas exposed to the topical anesthetics.
  • Study Duration: 1 visit
  • IRB Number: STU200401
  • ClinicalTrials.gov ID: NCT02427724
Emily Poon Samuelson, PhD
emily.poon( at )northwestern.edu
312-695-4761
Murad Alam, MD

Title: A Pilot Study Testing Fractional Radiofrequency Versus Fractional Photothermolysis for the Treatment of Acne Scars

  • 18 to 65 years old
  • Bilateral rolling acne scars on each side of their face, no active or ongoing acne and are in good health.
  • Will receive multiple treatments to their randomized side of the face 5 times total spaced 4 weeks apart
  • Study Duration: 36 weeks; 7 visits
  • IRB Number: STU84041
  • ClinicalTrials.gov ID: NCT01976260
Emily Poon Samuelson, PhD
emily.poon( at )northwestern.edu
312-695-4761
Murad Alam, MD

Title: Effect of Multiple Subcisions on Rolling Acne Scars

  • 8 to 65 years old with bilateral 2x2 cm areas of ice pick and/or boxcar acne scars on their face.
  • Will receive fractional radiofrequency treatment to one randomized side of the face, while the other side of the face will receive fractional photothermolysis treatment.  Three treatments spaced 4 weeks apart.
  • Study Duration: 16 weeks; 4 visits
  • IRB Number: STU97928
  • ClinicalTrials.gov ID: NCT02216864
Emily Poon Samuelson, PhD
emily.poon( at )northwestern.edu
312-695-4761
Murad Alam, MD

Title: Cyrolipolysis vs Cyrolipolysis and Subcision for Cellulite

  • Female Subjects 18-65 years old, who have cellulite on their outer thigh area.
  • Will receive one treatment of cryolipolysis to one outer thigh while the other thigh will receive one treatment of cryolipolysis and subcision.
  • Study Duration: 3 months; 1 treatment visit, 2 follow-up visits at 1 week and 3 months after treatment, and 1 follow-up phone call at 3 weeks after treatment.
  • IRB Number: STU200346
  • ClinicalTrials.gov ID: NCT02427698
Emily Poon Samuelson, PhD
emily.poon( at )northwestern.edu
312-695-4761
Murad Alam, MD

Title: Treatment of Facial Flushing With Botulinum Toxin A Injections

  • 18 to 65 years old with persistent facial flushing
  • One side of the face will be randomized to receive one administration of botulinum toxin injections.
  • Study Duration: 8 weeks; 1 treatment visit, and follow-up visits at week 1, week 4, and week 8
  • IRB Number: STU97514
  • ClinicalTrials.gov ID: NCT02216838
Emily Poon Samuelson, PhD
emily.poon( at )northwestern.edu
312-695-4761
Murad Alam, MDTitle: A Pilot Study Testing Salicylic Acid Peels Versus Glycolic Acid Peels for the Treatment of Melasma
  • 18 years or older, 2 x 2 cm patch of melasma on each side of the face (forehead or cheek)
  • Will receive salicyclic acid peel to one side of the face, while the other side of the face will receive glycolic acid peel; 4 treatments spaced 4 weeks apart.
  • Study Duration: 16 weeks; 5 visits
  • IRB Number: STU84250
  • ClinicalTrials.gov ID: NCT01976286
Emily Poon Samuelson, PhD
emily.poon( at )northwestern.edu
312-695-4761
Murad Alam, MDTitle: Patient Satisfaction in Cutaneous Surgery
  • 18 to 80 years older
  • Study Duration: day of surgery visit
  • IRB Number: STU55818
  • ClinicalTrials.gov ID: NCT01535963
Emily Poon Samuelson, PhD
emily.poon( at )northwestern.edu
312-695-4761
Murad Alam, MDTitle: Postoperative Care of Sutured Wounds This study is enrolling participants by invitation only.
  • 18 to 65 years old and are currently undergoing a dermatologic surgery procedure
  • Will be randomized to either saline or hydrogen peroxide to clean the sutured site.
  • Study Duration: 2 weeks; 2 visits
  • IRB Number: STU200234
  • ClinicalTrials.gov ID: NCT02383992
Erin Ibler
erin.ibler( at )northwestern.edu
Jonathan Silverberg, MDTitle: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 study to Evaluate the Safety and Efficacy of Baricitinib in Patients with Moderate-to Severe-Atopic Dermatitis
  • 18 and older
  • Diagnosed with moderate-severe atopic dermatitis
  • Study Duration: 6 months, study visits approximately 1/month 
  • IRB Number: STU00202196
  • ClinicalTrials.gov ID: NCT02576938
Erin Ibler, MD
erin.ibler( at )northwestern.edu
Amy Paller, MD

Title: Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis

  • 12 to 18; 18 and older
  • Diagnosed with moderate atopic dermatitis
  • Study Duration: 5 months--weekly visits for 3 weeks then monthly visits
  • IRB Number: STU00202962
  • ClinicalTrials.gov ID: NCT02564055
Estela Martinez-Escala, MD
estella.martinez-escala( at )northwestern.edu
312-860-5336
Joan Guitart MDTitle: Long-term Use of Romidepsin in Patients With CTCL
  • 18 to 89 years old
  • Diagnosis of Cutaneous T-cell Lymphoma who present to the Northwestern Medical Faculty Foundation Dermatology clinic between January 1, 2009 and December 31, 2014
  • Study Duration: 4 weeks; 1 visit per week
  • IRB Number: STU95649
  • ClinicalTrials.gov ID: NCT02296398
James Sabra
NUTransderm( at )northwestern.edu
Roopal Kundu, MD

Title: A Dermatologic Needs and Knowledge-Based Assessment of Transgender Women

  • Transgender Women; 18 years and over
  • Seeking participants to help assess transgender women's knowledge and needs related to dermatologic care.
  • Study Duration: 10-15 minutes, completing a one-time survey
  • IRB Number: 
  • ClinicalTrials.gov ID:
Marcella A Oliver
m-oliver2( at )northwestern.edu
Maria Colavincenzo, MDTitle: Use of Alternative Medicine Among Outpatients in Dermatology and Primary Care Clinics
  • 18 and older
  • Presents for a clinic appointment with a dermatologist or primary care physician
  • Study Duration: 5 minutes to complete survey 
  • IRB Number: STU67142
  • ClinicalTrials.gov ID: NCT01660139
Thy Huynh, MD
thy.huynh( at )northwestern.edu
312-227-6486
Amy S Paller, MD

Title: Defining the Unique Skin and Blood Biomarkers of Pediatric Atopic Dermatitis

  • 3 months to 17 years with moderate to severe atopic dermatitis
  • Subjects may have no inflammatory disease or atopy (urticaria, food allergy, allergic rhinitis or conjunctivitis, asthma)
  • Subjects have moderate to severe atopic dermatitis, with either new onset disease within the last 6 months or with an serious aggravated atopic dermatitis
  • Subjects should not have administered systemic immunosuppressant therapy in the month before the study
  • Study Duration: return to the study site each year (1 year [+/- 2 weeks] following each study visit) up until the age of 12 year
  • IRB Number: 2013-15143
  • ClinicalTrials.gov ID: NCT01782703
Thy Huynh, MD
thy.huynh( at )northwestern.edu
312-227-6486
Anthony J Mancini, MD

Title: Sildenafil for the Treatment of Lymphatic Malformations

  • 6 months - 10 years, minimum weight of 8 kg
  • Clinical diagnosis of lymphatic malformation that appears to be over 3 cm in greatest diameter in order to be evaluated for entry
  • Lymphatic malformation cause enough disability for the subject that requires them to consider systemic therapy
  • Required MRI examination to confirm that the lymphatic malformation is present and is greater than 3 cm in diameter
  • Study Duration: 20 weeks
  • IRB Number: 2015-417
  • ClinicalTrials.gov ID: NCT02335242
Tinatin Kiguradze
tinatin.kiguradze( at )northwestern.edu
Anne E Laumann, MBCHB

Title: Efficacy of Ustekinumab Followed by Abatacept for the Treatment of Psoriasis Vulgaris (PAUSE)

  • 18 to 65 year old who have a diagnosis of plaque psoriasis for at least 6 months and are willing to forgo other available psoriasis therapies, live vaccines, and pregnancy during the trial.
  • Study Duration: 2 years, 25 visits
  • IRB Number: STU98164
  • ClinicalTrials.gov ID: NCT01999868